Fallopian Tube Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

PLX038 for the Treatment of Patients With Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Ovarian Carcinoma; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Per itoneal Cancer AJCC v8 Interventions: Procedure: Biopsy; Drug: Pegylated SN-38 Conjugate PLX038 Sponsors: Mayo Clinic; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 20, 2022 Category: Research Source Type: clinical trials

Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer Interventions: Drug: Mirvetuximab soravtansine plus Bevacizumab; Drug: Bevacizumab Sponsor: ImmunoGen, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2022 Category: Research Source Type: clinical trials